Nasal Polyps Treatment Market to Reach $4.24 Billion, Globally, by 2030 at 5.6% CAGR 2021 to 2030

Allied Market Research published a report, titled, "Nasal Polyps Treatment Market by Type of Treatment (Corticosteroids, Antibiotics, Leukotriene Inhibitors, and Others), Route of Administration (Oral, Nasal, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2030.". According to the report, the global nasal polyps treatment industry generated $2.48 billion in 2020, and is anticipated to generate $4.24 billion by 2030, witnessing a CAGR of 5.6% from 2021 to 2030.

𝐏𝐫𝐢𝐦𝐞 𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐧𝐭𝐬 𝐨𝐟 𝐠𝐫𝐨𝐰𝐭𝐡
Rapid utilization of minimally-invasive surgeries, rise in prevalence of chronic rhinosinusitis, and huge product pipeline drive the growth of the global nasal polyps treatment market. However, high cost and complications associated with sinus surgeries, and adverse reactions associated with steroid therapies hinder the market growth. On the other hand, technological improvement in nasal polyps treatment present new opportunities in the coming years.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝑹𝒆𝒑𝒐𝒓𝒕
https://www.alliedmarketresearch.com/request-sample/14043

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-19 𝐨𝐧 𝐍𝐚𝐬𝐚𝐥 𝐏𝐨𝐥𝐲𝐩𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭-

During the Covid-19 pandemic, demand for antibiotics increased due to symptoms associated with nasal polyps such as loss in sense of smell and taste, feeling of congestion, and difficulty in breathing.
Sinus infection and COVID-19 share similar symptoms, it is important to know the difference. As a result, in the ongoing pandemic, the nasal polyps treatment market is expected to grow, owing to increase in demand for diagnostic tests and antibiotics.
This way, the outbreak of COVID-19 has positively impacted the nasal polyps treatment market.

𝐓𝐡𝐞 𝐧𝐚𝐬𝐚𝐥 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on route of administration, the nasal segment held the highest market share in 2020, accounting for more than half of the global nasal polyps treatment market, and is estimated to maintain its leadership status throughout the forecast period, owing to nasal delivery route being an encouraging way of delivering drugs into the body as compared to other drug delivery route such as oral and others. Moreover, this segment is projected to manifest the highest CAGR of 6.0% from 2021 to 2030. Another segment discussed in the report is oral.

𝐓𝐡𝐞 𝐫𝐞𝐭𝐚𝐢𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on distribution channel, the retail pharmacies segment accounted for the largest share in 2020, contributing nearly half of the global nasal polyps treatment market, and is projected to maintain its lead position during the forecast period, owing to increase in preference of retail pharmacies by the population, as it is the oldest and most conventional medium distributing the nasal polyps treatment products such as corticosteroids, antibiotics and leukotriene inhibitors to the consumers. Moreover, this segment is expected to portray the largest CAGR of 6.1% from 2021 to 2030. Other segments discussed in the report are hospital pharmacies and online pharmacies.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲- https://www.alliedmarketresearch.com/purchase-enquiry/14043

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐧𝐜𝐞 𝐛𝐲 2030

Based on region, North America held the highest market share in terms of revenue 2020, accounting for nearly half of the global nasal polyps treatment market, owing to presence of major key players in the countries like the U.S. In addition, presence of a large population with nasal polyps, increase in incidences of CRSwNP, surge in the number of sinus surgeries are factors that supplement the growth of the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 7.5% from 2021 to 2030. This is due to growth in healthcare infrastructure, rise in prevalence of nasal polyps and its associated disorders such as asthma and sinusitis, and increase n disposable incomes.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:-
AstraZeneca plc.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Intersect ENT Inc.
Merck & Co Inc.
Novartis International AG
OptiNose US
Regeneron Pharmaceuticals Inc.
Sanofi S.A
Teva Pharmaceutical Industries Ltd.

𝑲𝒏𝒐𝒘 𝑴𝒐𝒓𝒆 https://www.alliedmarketresearch.com/nasal-polyps-treatment-market-A13674

𝐒𝐢𝐦𝐢𝐥𝐚𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐟𝐨𝐫 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐃𝐨𝐦𝐚𝐢𝐧
𝐍𝐞𝐱𝐭 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐢𝐧 𝐀𝐠𝐫𝐢𝐜𝐮𝐥𝐭𝐮𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/next-generation-genetic-engineering-in-agriculture-market-A12370

𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/circulating-tumor-cell-market-A11918

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.